(Q34161050)

English

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Donald L Trump

1

1 reference

Europe PubMed Central

31 July 2017

Heather Payne

2

1 reference

Europe PubMed Central

31 July 2017

Kurt Miller

3

1 reference

Europe PubMed Central

31 July 2017

Johann S de Bono

4

1 reference

Europe PubMed Central

31 July 2017

Joe Stephenson

5

1 reference

Europe PubMed Central

31 July 2017

Howard A Burris

6

1 reference

Europe PubMed Central

31 July 2017

Faith Nathan

7

1 reference

Europe PubMed Central

31 July 2017

Maria Taboada

8

1 reference

Europe PubMed Central

31 July 2017

Thomas Morris

9

1 reference

Europe PubMed Central

31 July 2017

Andreas Hubner

10

1 reference

Europe PubMed Central

31 July 2017

publication date

26 January 2011

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

71

1 reference

Europe PubMed Central

31 July 2017

12

1 reference

Europe PubMed Central

31 July 2017

1264-1275

1 reference

Europe PubMed Central

31 July 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Mechanisms leading to the development of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Endothelin receptors as novel targets in tumor therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

The endothelin axis: emerging role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Docetaxel-based combination therapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

The importance of endothelin-1 for vascular dysfunction in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21342

21 January 2018

Identifiers

10.1002/PROS.21342

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34161050&oldid=1966849228"